Parameter | |
---|---|
Age (years), median [IQR] | 60 [58–63] |
Sex, no. (%) | |
M/F | 46 (85)/8 (15) |
BMI, kg/m2, median [IQR] | 27 [25.5–28.1] |
Blood pressure (mmHg), median [IQR] | |
Systolic | 130 [120–131.2] |
Diastolic | 80 [70–80] |
Hypertension, no. (%) | 15 (28) |
Smoke, no. (%) | 43 (80) |
Cholesterol (mg/dL), median [IQR] | |
Total | 172 [149.5–189] |
HDL | 42.5 [35–51] |
LDL | 103 [68–128] |
Triglycerides (mg/dL), median [IQR] | 127 [105.2–151.5] |
Glycemia (mg/dL), median [IQR] | |
Baseline | 87 [80–90.2] |
2 h | 109 [93–126.7] |
Glycated hemoglobin (%), median [IQR] | 5.2 [5.1–5.5] |
Insulin (µU/mL), median [IQR] | 3.8 [3–6] |
HOMA IR, median [IQR] | 0.78 [0.59–1.31] |
Creatinine (mg/dL), median [IQR] | 1 [0.87–1.1] |
Hemoglobin (mg/dL), median [IQR] | 14.3 [13.3–15.2] |
Adiponectin (µg/mL), median [IQR] | 11 [9.7–13.2] |
Adiponectin, no. (%) | |
Pathologic | 13 (24) |
Resistin (ng/mL), median [IQR] | 7 [4–9] |
Resistin, no. (%) | |
Pathologic | 8 (15) |
TNF-alpha (ng/mL), median [IQR] | 8.5 [7–11] |
TNF-alpha, no. (%) | |
Pathologic | 6 (11) |
Site of stenosis at first PCI, no. (%) | |
IVA | 25 (46) |
CX | 10 (19) |
DX | 19 (35) |
Follow-up duration (months), median [IQR] | 29.5 [14.7–34] |
Re-PCI, no. (%) | 4 (7) |
Time re-PCI, median [IQR] | 8.5 [4–15.75] |
Site of re-PCI, no. (%) | |
IVA | 3 (75) |
CX | 0 (−) |
DX | 1 (25) |
New PCI, no. (%) | 5 (9) |
Time new PCI, median [IQR] | 29 [IQR 12–33.5] |
Site of new-PCI, no. (%) | |
IVA | 2 (40) |
CX | 1 (20) |
DX | 2 (40) |
Death, no. (%) | |
Cardiovascular/other causes | − /1 (2) |